Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Prosigna / PAM50 Interpreter

The Prosigna (PAM50) gene signature provides a Risk of Recurrence (ROR) score (0-100) for postmenopausal women with HR+, HER2-, early-stage breast cancer.

Evidence-based context for fast calculator use

Purpose:
Prosigna PAM50 interprets Risk of Recurrence score to stratify 10-year distant recurrence risk in HR+/HER2- early-stage breast cancer.
Population:
patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment
Factors:
ROR Score, Nodal Status
Reference:
Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial. Ann Oncol. 2014;25(2):339-345.
HomeProsigna / PAM50 Interpreter
Pin your most used calculators here by clicking the star in the dropdown.

Prosigna / PAM50 Interpreter

Clinical Context & Background

The Prosigna (PAM50) gene signature provides a Risk of Recurrence (ROR) score (0-100) for postmenopausal women with HR+, HER2-, early-stage breast cancer. It assigns an intrinsic subtype (Luminal A/B, HER2-E, Basal-like) and stratifies the 10-year risk of distant recurrence to guide adjuvant therapy decisions.
Primary Source EvidenceGnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial. Ann Oncol. 2014;25(2):339-345.
Formula Logic
Interpretation of ROR Score (0-100) based on Nodal Status.

Reference Data

Nodal StatusROR RangeRisk Category10y Distant Recurrence
Node Negative0 - 40Low< 10%
Node Negative41 - 60IntermediateVaries
Node Negative61 - 100High> 20%
Node Positive (1-3)0 - 15Low< 10%
Node Positive (1-3)16 - 40IntermediateVaries
Node Positive (1-3)41 - 100High> 20%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Prosigna / PAM50 Interpreter when prosigna PAM50 interprets Risk of Recurrence score to stratify 10-year distant recurrence risk in HR+/HER2- early-stage breast cancer.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Node Negative through Node Positive (1-3).
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Integrate the result with invasive versus in-situ status, stage, receptor biology, treatment timing, genomic testing, comorbidity, and patient goals.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not interchange screening-risk, DCIS, invasive prognosis, genomic, and post-neoadjuvant tools.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment

How to apply this result

For a representative case, verify ROR Score, Nodal Status, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Breast Cancer hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

BI-RADS Score (Breast)Nottingham Prognostic Index (NPI)MSKCC DCIS Nomogram — Breast Cancer DCIS Recurrence Risk Calculator

Frequently Asked Questions

When should Prosigna / PAM50 Interpreter be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can Prosigna / PAM50 Interpreter determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.